SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Stock-Based Compensation
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Stock-Based Compensation of $27.51 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was -$7.51K, a 116.03% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $35.02K, a 93.48% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $214.75K, a 574.09% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $134.32K, a 196.67% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $932.97K, a 259.19% increase from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $259.74K, a 42.75% increase from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $181.96K, a 23.40% decline from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $237.55K, a 73.90% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$7.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $27.51K 10-Q · filed 2026-09-24 | $242.26K derived: sum of 3 quarters · filed 2026-09-24 | $376.57K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2026-03-31 | $35.02K 10-Q · filed 2026-05-15 | $249.77K derived: sum of 2 quarters · filed 2026-05-15 | $384.09K derived: sum of 3 quarters · filed 2026-05-15 | $430.94K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-12-31 | $214.75K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $349.07K derived: sum of 2 quarters · filed 2026-03-31 | $395.92K derived: sum of 3 quarters · filed 2026-09-24 | $932.97K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $134.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $181.17K derived: sum of 2 quarters · filed 2026-09-24 | $718.22K 10-Q · filed 2025-11-13 | $750.08K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-06-30 | $46.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $583.90K 10-Q · filed 2026-09-24 | $615.76K derived: sum of 3 quarters · filed 2026-09-24 | $661.03K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-03-31 | $537.05K 10-Q · filed 2026-05-15 | $568.90K derived: sum of 2 quarters · filed 2026-05-15 | $614.18K derived: sum of 3 quarters · filed 2026-05-15 | $685.34K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $31.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $77.13K derived: sum of 2 quarters · filed 2026-03-31 | $148.29K derived: sum of 3 quarters · filed 2026-03-31 | $259.74K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $45.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $116.44K derived: sum of 2 quarters · filed 2025-11-13 | $227.89K 10-Q · filed 2025-11-13 | $314.41K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $71.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $182.61K 10-Q · filed 2025-08-13 | $269.13K derived: sum of 3 quarters · filed 2025-08-13 | $306.72K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $111.45K 10-Q · filed 2025-05-08 | $197.97K derived: sum of 2 quarters · filed 2025-05-08 | $235.55K derived: sum of 3 quarters · filed 2025-05-08 | $285.08K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $86.52K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $124.11K derived: sum of 2 quarters · filed 2025-02-26 | $173.63K derived: sum of 3 quarters · filed 2025-02-26 | $181.96K 10-K · filed 2025-02-26 | |
| 2023-09-30 | $37.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $87.11K derived: sum of 2 quarters · filed 2024-11-13 | $95.44K 10-Q · filed 2024-11-13 | -$23.75K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $49.52K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | $57.85K 10-Q · filed 2024-09-04 | -$61.33K derived: sum of 3 quarters · filed 2024-09-04 | -$37.66K derived: sum of 4 quarters · filed 2024-09-04 | |
| 2023-03-31 | $8.33K 10-Q/A · filed 2024-09-04 | -$110.85K derived: sum of 2 quarters · filed 2024-09-04 | -$87.19K derived: sum of 3 quarters · filed 2024-09-04 | $79.35K derived: sum of 4 quarters · filed 2024-09-04 | |
| 2022-12-31 | -$119.19K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | -$95.52K derived: sum of 2 quarters · filed 2024-09-04 | $71.01K derived: sum of 3 quarters · filed 2024-09-04 | $237.55K 10-K/A · filed 2024-09-04 | $403.96K 10-K · filed 2023-03-15 |
| 2022-09-30 | $23.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $190.20K derived: sum of 2 quarters · filed 2023-11-13 | $356.73K 10-Q · filed 2023-11-13 | $899.25K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $166.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $333.07K 10-Q · filed 2023-08-14 | $875.58K derived: sum of 3 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $166.53K 10-Q · filed 2023-05-25 | $709.05K derived: sum of 2 quarters · filed 2023-05-25 | |||
| 2021-12-31 | $542.52K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $910.07K 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $367.55K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |